New hope for managing diabetes in cystic fibrosis?
NCT ID NCT06149793
Summary
This small pilot study is testing if adding the diabetes drug empagliflozin to standard insulin therapy is safe and helps control blood sugar in overweight adults with cystic fibrosis-related diabetes (CFRD). The main goal is to gather initial safety and feasibility data to see if a larger, more definitive trial is warranted. Participants will try both the drug and a placebo in a random order to compare the effects.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CYSTIC FIBROSIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
University of Minnesota
Minneapolis, Minnesota, 55455, United States
Conditions
Explore the condition pages connected to this study.